Corcept Therapeutics Inc [CORT] stock prices are up 109.08% to $114.22 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CORT shares have gain 92.06% over the last week, with a monthly amount glided 88.54%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Corcept Therapeutics Inc [NASDAQ: CORT] stock has seen the most recent analyst activity on November 06, 2023, when Truist upgraded its rating to a Buy and also boosted its price target to $38 from $29. Previously, SVB Securities started tracking the stock with Market Perform rating on April 11, 2023, and set its price target to $25. On April 04, 2023, Piper Sandler initiated with a Overweight rating and assigned a price target of $27 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $22 on February 15, 2023. Truist downgraded its rating to a Hold but $30 remained the price target by the analyst firm on August 01, 2022. Jefferies upgraded its rating to Buy for this stock on July 27, 2022, and upped its price target to $35.
The stock price of Corcept Therapeutics Inc [CORT] has been fluctuating between $20.84 and $75.00 over the past year. Currently, Wall Street analysts expect the stock to reach $80 within the next 12 months. Corcept Therapeutics Inc [NASDAQ: CORT] shares were valued at $114.22 at the most recent close of the market. An investor can expect a potential drop of -29.96% based on the average CORT price forecast.
Analyzing the CORT fundamentals
The Corcept Therapeutics Inc [NASDAQ:CORT] reported sales of 675.04M for trailing twelve months, representing a surge of 34.33%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.24%, and Net Profit Margin reading is 0.21%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.23 and Total Capital is 0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 95.42 points at the first support level, and at 76.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 125.17, and for the 2nd resistance point, it is at 136.13.
Ratios To Look Out For
It’s worth pointing out that Corcept Therapeutics Inc [NASDAQ:CORT]’s Current Ratio is 3.35. In addition, the Quick Ratio stands at 3.26 and the Cash Ratio stands at 0.91. Considering the valuation of this stock, the price to sales ratio is 17.85, the price to book ratio is 17.67 and price to earnings (TTM) ratio is 92.63.
Transactions by insiders
Recent insider trading involved Maduck Sean, Officer, that happened on Mar 31 ’25 when 100000.0 shares were purchased. Officer, Lyon Joseph Douglas completed a deal on Mar 31 ’25 to buy 0.2 million shares. Meanwhile, Lyon Joseph Douglas sold 421.0 shares on Mar 24 ’25.
